Buy or sell guide
Should I Buy GILD Stock Right Now?
A fast read on Wall Street conviction, live analyst commentary on X, and current valuation context for Gilead Sciences, Inc..
Updated 2026-06-22
Wall Street currently rates GILD buy with a 12-month price target of $162 (+30.7% upside). The sections below cover the bull case, key risks, and latest earnings context for GILD.
Wall Street
Buy58 analystsConsensus target
$162 target (+30.7%)Current price $123.76Analyst sentiment
No recent analyst posts capturedWaiting for fresh postsEarnings context
EPS beat 6.3%Reported Thu May 07Wall Street verdict
Should I Buy GILD Stock? Here's What Analysts Think
58 analysts currently cover GILD. Below is their consensus rating, price target range, and implied upside.
According to 58 analysts, Gilead Sciences, Inc. (GILD) is rated Buy with a consensus 12-month price target of $162 — representing 31% upside from today's price of $124. The bull case target is $180, the bear case is $122.
GILDBuy
From 58 analyst ratings- Current price
- $123.76
- Consensus Target
- $162 (+30.7% upside)
- Coverage
- 58 analyst ratings
High target$180
Low target$122
At $123.76, the consensus setup implies +30.7% versus the 12-month target.
- 38 of 58 analysts lean Buy or Strong Buy, while 19 stay on Hold and 1 lean bearish.
- Forward valuation data is limited right now, which makes the target more useful than the multiple.
- Analysts span a wide range from $122 to $180, so conviction matters as much as the consensus target.
Below, compare that institutional answer with the live analyst commentary on X for GILD right now.
Analyst ratings update weekly. Get GILD's next verdict in your inbox.
Free. No account needed. Unsubscribe any time.
1 of 1 analysts raised targetsMaxim Group $165
Jun 2026Live commentary on X
What Analysts Are Saying About Gilead Sciences, Inc. Right Now
Real posts from high-reach stock analysts mentioning GILD, shown exactly as written. Sorted by engagement — most discussed first.
No recent posts captured
No high-reach analysts have posted about GILD in the last 7 days. Check back after the next earnings release or market-moving event.
Should you buy GILD?
Is GILD a Buy, Hold, or Sell Right Now?
A structured look at the bull case, the risks, and the most recent earnings execution for GILD before you decide whether to buy, hold, or sell.
Current setup
GILD beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
Bull Case
What keeps the long thesis intact
- Strong Product PipelineGilead is expected to launch four new products in 2026, including anito-cel CAR T-cell therapy with a 96% response rate, awaiting FDA approval.
- Robust HIV FranchiseGilead's HIV business, led by treatments like Biktarvy, remains a significant revenue driver, with lenacapavir receiving funding for expanded access.
- Strategic AcquisitionsThe acquisition of Arcellx enhances Gilead's oncology pipeline, indicating a strategic shift beyond its traditional HIV focus.
- Positive Financial OutlookAnalysts project continued EPS growth through 2026, with the stock trading below many price targets, suggesting undervaluation.
Wall Street rates GILD buy, giving the bull case institutional backing from 58 analysts.
Watch Out For
What can break the setup quickly
- Integration RisksRecent large acquisitions may complicate integration, risking financial performance and investor confidence.
- Uncertain Pipeline SuccessThe success of new products like Yeztugo and anito-cel is not guaranteed, and any sales shortfall could compress stock prices.
- High Debt LevelsSignificant investments in acquisitions have led to high debt, raising concerns in a rising interest rate environment.
- Competitive PressuresGilead faces ongoing competition and potential revenue impacts from patent expirations on key drugs.
Watch whether new negative commentary on GILD points to these structural risks or is simply reacting to short-term price moves.
GILD Earnings Reaction — What the Last Quarter Showed
Last Quarter
- EPS
- $2.03 vs $1.91 est.Beat 6.3%
- Revenue
- $7.0B vs $6.9B est.Beat 0.7%
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into GILD consensus models and risk factors.
View Analysis
Should I Buy GILD?
Wall Street verdict, signals, and target summaries.
See Verdict
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
GILD — Frequently Asked Questions
Quick answers to the most common questions about buying GILD stock.
Should I buy GILD stock right now?
Verdict
GILD looks attractive at current levels — Wall Street's consensus rating is "Buy" with a $162 price target (+30.7% upside from $123.76). This is informational only — verify the data and consider your own risk tolerance before deciding.
Is now a good time to buy GILD?
Timing
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +30.7% upside to the $162 target. In the past 30 days, 1 of 1 covering analysts raised their price targets — a bullish signal.
What is the price target for GILD stock?
Price Target
GILD's consensus 12-month price target is $162, set by 58 Wall Street analysts. The bull case high is $180 and the bear case low is $122. From the current price of $123.76, this implies +30.7% upside.
Is GILD overvalued or undervalued?
Valuation
GILD appears undervalued — the $162 consensus target is +30.7% above today's $123.76. It trades at a forward P/E of 0.0x. Targets range from $122 (bear) to $180 (bull), reflecting different assumptions about growth and margins.
Should I buy GILD before earnings?
Earnings
GILD reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $162 target. Consider position sizing rather than going all-in pre-print.
What are analysts saying about GILD stock?
Coverage
Of 58 analysts covering Gilead Sciences, Inc. (GILD): 0 Strong Buy, 38 Buy, 19 Hold, 1 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $162 (range $122–$180). Bullish analysts outnumber bearish by more than 2-to-1.
What are the risks of buying GILD stock?
Risks
1 of the 58 analysts covering GILD rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on Gilead Sciences, Inc..
This page is for informational purposes only and does not constitute financial advice. Always conduct your own research before investing.